Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (1983)	2/9/2002 4:44:51 PM
From: Fred Levine	Read Replies (1) \| Respond to of 2515

What you said is correct; that survival rates are a long-term (5 yrs) variable. How could a drug that is being used for 3 yrs present survival rate? Therefore, tumor shrinkage -- especially of refractory tumors-- is a reasonable dependent variable. If my figures about shrinkage are wrong, let me know -- and because they are just my memory, they may well be. But the results indicated that Erbotux is a very promising drug that, IMO, the FDA should facilitate. If, however, the data are blemished, you have a powerful point. However, saying data are blemished is a serious accusation that I'm in no position to determine. fred